

In Vitro Monoclonal Antibodies Market - 2023-2031

<https://marketpublishers.com/r/I6CF145F7E1CEN.html>

Date: February 2025

Pages: 200

Price: US\$ 2,999.00 (Single User License)

ID: I6CF145F7E1CEN

Abstracts

The In Vitro Monoclonal Antibodies Market was valued at US\$ 5.41 billion in 2023 and is anticipated to reach US\$ 8.4 billion by 2031, at a CAGR of 0.057 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the In Vitro Monoclonal Antibodies Market.

This report delivers a comprehensive overview of the In Vitro Monoclonal Antibodies Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding In Vitro Monoclonal Antibodies Market. The In Vitro Monoclonal Antibodies Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

In Vitro Monoclonal Antibodies Market Scope:

By MAB Functionality

Naked Monoclonal Antibodies

Conjugated Monoclonal Antibodies

Bispecific Monoclonal Antibodies

By MAB Structure

Murine

Chimeric

Humanized

Human

By Technology

Hybridoma technology

Phage display

Single B-cell antibody technology

Recombinant antibody production

Key Players

Amgen Inc.

Biogen

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

GlaxoSmithKline plc

Novartis AG

Pfizer Inc.

Sanofi

Merck & Co., Inc.

Major Highlights

This report delivers a comprehensive overview of the In Vitro Monoclonal Antibodies Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding In Vitro Monoclonal Antibodies Market. The In Vitro Monoclonal Antibodies Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the

latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by MAB Functionality
- 3.2. Snippet by MAB Structure
- 3.3. Snippet by Technology
- 3.4. Snippet by Application
- 3.5. Snippet by End-User

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increasing Prevalence of Chronic Diseases
 - 4.1.2. Restraints
 - 4.1.2.1. High Costs of Development and Treatment
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis
- 5.6. Patent Analysis
- 5.7. SWOT Analysis
- 5.8. DMI Opinion

6. BY MAB FUNCTIONALITY

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Functionality

6.1.2. Market Attractiveness Index, By MAB Functionality

6.2. Naked Monoclonal Antibodies*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Conjugated Monoclonal Antibodies

6.4. Bispecific Monoclonal Antibodies

7. BY MAB STRUCTURE

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Structure

7.1.2. Market Attractiveness Index, By MAB Structure

7.2. Murine*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Chimeric

7.4. Humanized

7.5. Human

8. BY TECHNOLOGY

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

8.1.2. Market Attractiveness Index, By Distribution Channel

8.2. Hybridoma technology*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Phage display

8.4. Single B-cell antibody technology

8.5. Recombinant antibody production

9. BY REGION

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Functionality

9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Structure

9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.2.8.1. The U.S.

9.2.8.2. Canada

9.2.8.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Functionality

9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Structure

9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.3.8.1. Germany

9.3.8.2. UK

9.3.8.3. France

9.3.8.4. Italy

9.3.8.5. Spain

9.3.8.6. Rest of Europe

9.4. South America

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Functionality

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Structure

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.4.8.1. Brazil

9.4.8.2. Argentina

9.4.8.3. Rest of South America

9.5. Asia-Pacific

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Functionality

9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Structure

9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.5.8.1. China

9.5.8.2. India

9.5.8.3. Japan

9.5.8.4. South Korea

9.5.8.5. Rest of Asia-Pacific

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Functionality

9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By MAB Structure

9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. COMPETITIVE LANDSCAPE

10.1. Competitive Scenario

10.2. Market Positioning/Share Analysis

10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

11.1. Amgen Inc.*

11.1.1. Company Overview

11.1.2. Product Portfolio and Description

11.1.3. Financial Overview

11.1.4. Key Developments

11.2. Biogen

11.3. Bristol-Myers Squibb Company

11.4. Eli Lilly and Company

- 11.5. F. Hoffmann-La Roche Ltd
- 11.6. GlaxoSmithKline plc
- 11.7. Novartis AG
- 11.8. Pfizer Inc.
- 11.9. Sanofi
- 11.10. Merck & Co., Inc. (*LIST NOT EXHAUSTIVE)

12. APPENDIX

- 12.1. About Us and Services
- 12.2. Contact Us

I would like to order

Product name: In Vitro Monoclonal Antibodies Market - 2023-2031

Product link: <https://marketpublishers.com/r/l6CF145F7E1CEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l6CF145F7E1CEN.html>